| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
2,6-Dibromophenol does not have a well-defined pharmacological target, as it is primarily an industrial chemical and intermediate. It may interact with various enzymes and receptors as a xenobiotic, but its specific binding targets have not been fully characterized. The compound's bromine atoms make it reactive and potentially toxic. It is not used as a therapeutic agent.
|
|---|---|
| ln Vitro |
2,6-Dibromophenol does not possess significant pharmacological activity as a pure compound in typical in vitro assays, as it is primarily used as a chemical intermediate. Studies may involve evaluating its reactivity in organic synthesis or its presence as a metabolite in marine organisms. The compound is also used in the production of 3,4,5-trimethoxybenzaldehyde and 2-(2,6-dibromophenoxy)ethylbromide. It is not studied for specific biological activities.
|
| ln Vivo |
In vivo activity of 2,6-Dibromophenol is related to its role as a marine metabolite and its use as an intermediate in the manufacture of various products. The compound is not used therapeutically, and comprehensive in vivo studies evaluating its pharmacokinetic properties, efficacy, and safety are limited. Its toxicity profile is primarily related to its use as an industrial chemical. It is an irritant.
|
| Enzyme Assay |
In vitro enzyme/receptor binding experiments for 2,6-Dibromophenol are not typical, as it is a chemical intermediate rather than a pharmacologically active compound. Studies may involve measuring its reactivity with various reagents or its presence as a metabolite in marine organisms. Its chemical properties are characterized using standard analytical methods such as GC and HPLC. The compound is also used as a reference standard in analytical chemistry.
|
| Cell Assay |
In vitro cellular experiments for 2,6-Dibromophenol are not typical, as it is a chemical intermediate rather than a pharmacologically active compound. The compound may be used in studies to evaluate its cytotoxicity or its metabolism in cell lines. However, comprehensive in vitro cellular studies are limited. The compound's bromine atoms can make it toxic to cells.
|
| Animal Protocol |
In vivo animal experiments for 2,6-Dibromophenol are not typical, as it is a chemical intermediate rather than a drug candidate. Studies may involve administering the compound to animals to study its metabolism or toxicity. The compound is an irritant and should be handled with care. Comprehensive in vivo studies evaluating its pharmacokinetic properties are limited.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,6-Dibromophenol have not been extensively characterized. With a molecular weight of 251.90, the compound is expected to have moderate lipophilicity. It is soluble in ethanol, ether, benzene, carbon disulfide, hot water, and alkali solutions. It has a melting point of 53-58°C and a boiling point of 255-256°C. Detailed pharmacokinetic studies are limited.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,6-Dibromophenol indicate that it is an irritant. As a brominated phenol, it may cause skin and eye irritation and may be harmful if ingested or inhaled. The compound should be handled with care, and standard safety protocols for handling halogenated phenols should be followed, including the use of personal protective equipment and working in a well-ventilated area.
|
| Additional Infomation |
2,6-Dibromophenol is a dibromophenol in which both hydrogen atoms adjacent to the phenolic hydroxyl group are replaced by bromine atoms. It is a marine metabolite. It is both a brominated hydrocarbon and a dibromophenol. Its structure is similar to that of 1,3-dibromobenzene.
2,6-Dibromophenol is a research chemical that has not entered clinical trials or received regulatory approval for therapeutic use. It is primarily used as a chemical intermediate in the manufacture of insecticides, herbicides, preservatives, antiseptics, and disinfectants. The compound is also a marine metabolite and is used as a reference standard in analytical chemistry. It is also known as 2,6-DBPh. Further research is needed to explore its potential biological activities. |
| Molecular Formula |
C₆H₄BR₂O
|
|---|---|
| Molecular Weight |
251.90
|
| Exact Mass |
249.862
|
| CAS # |
608-33-3
|
| Related CAS # |
2,6-Dibromophenol-d3;1219803-14-1
|
| PubChem CID |
11847
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
256.6±0.0 °C at 760 mmHg
|
| Melting Point |
53-56 °C(lit.)
|
| Flash Point |
82.5±21.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.644
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
87.1
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SSIZLKDLDKIHEV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H4Br2O/c7-4-2-1-3-5(8)6(4)9/h1-3,9H
|
| Chemical Name |
2,6-dibromophenol
|
| Synonyms |
2,6Dibromophenol; 2,6 Dibromophenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~396.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9698 mL | 19.8491 mL | 39.6983 mL | |
| 5 mM | 0.7940 mL | 3.9698 mL | 7.9397 mL | |
| 10 mM | 0.3970 mL | 1.9849 mL | 3.9698 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
